米氮平与怡诺思治疗抑郁症的对照研究

目的:评价米氮平治疗抑郁的临床疗效和安全性。方法:对符合CCMD-3抑郁症诊断标准的57例抑郁症患者进行米氮平和万拉法辛缓释剂怡诺思的对照研究,其中米氮平组30例(15-45mg/d),怡诺思组27例(75～225mg/d),共6周。采用汉密顿抑郁量表HAMD和汉密顿焦虑量表HAMA评价疗效,副反应量表(TESS)评价不良反应。结果:经6周治疗后,米氮平组总有效率为87％,显效率为67％,怡诺思组分别为85％和68％,两组比较,差异无显著性(P>0.05)。两组的HAMD、HAMA评分治疗前后相比较差异有高度显著性(P<0.01);治疗5天后,两组之间比较差异无显著性(P>0.05)。米氮平组的不良反应相对少。结论:米氮平是一种安全、有效的薪一代抗抑郁药,适合临床使用。

A comparative study of mirtazapine and efexor xr for depressive patients

Objective: The aim of this study was to determine the efficacy and safety of mirtazapine to the depressive patients. Methods: A controlled study was carried out between 57 patients who met the CCMD - 3 criteria of maior depression and depressed episode.The 30 of total patients were treated with mirtazapine (15 -45mg/d) and others were treated with efexor xr (75-225mg/d) for 6 weeks.The efficacy were assessed by Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Scale (HAMA), and the safety was assessed by Treatment Emergent Symptom Scale (TESS) .Results:After six weeks treatment,the improvement rate and significant improvement rate of mirtazapine group and efexor xr group were 87% and 67%, 85% and 68% respectively (P>0.05) .The scores of HAMD and HAMA in two groups were statistical difference before and after treatment (P < 0.01 ) .There were lower side effects in mirtazapine group than efexor xr group.Conclusion: Mirtazapine is an effective antidepressant, with less side effects, better safety and rapid response compared with efexor xr,suiting for clinical use.